EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Investigation on Linker Modifications of Cyanoguanidine‐Based P2X7 Receptor Antagonists

Taylor R Garrett, Jayson Gilchrist, Andre D J McKenzie, Fayaz Ali Larik, Jonathan J Danon, Eryn L Werry, Michael Kassiou iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Taylor R Garrett und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia. Hauptthemen laut MEDLINE: Purinergic P2X Receptor Antagonists, Guanidines, Receptors, Purinergic P2X7. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite their acknowledged significance in the inflammatory signalling cascade across a range of disease states, P2X7R antagonists have not yet proven to be effective in clinical trials. In this study, we present findings on P2X7 receptor antagonists that are based on a core adamantyl‐cyanoguanidine‐quinoline lead. To investigate the specific features of the cyanoguanidine moiety that influence compound potency we carried out a structure‐activity relationship (SAR) study. Compound potency was assessed using an in vitro dye‐uptake assay measuring P2X7R pore formation. While none of the compounds displayed superior potency to the lead, we established key structural requirements for potent P2X7R antagonism. An additional SAR using different aryl groups was performed based on the promising activity displayed by the squaramide derivative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2X Receptor AntagonistsGuanidinesReceptors, Purinergic P2X7Structure-Activity RelationshipHumansMolecular StructureDose-Response Relationship, DrugQuinolinesHEK293 Cells

Stichwörter der Autor:innen

P2X receptorP2X(7)RP2X7R antagonistcyanoguanidineinflammationsquaramidethiourea

Substanzen

Purinergic P2X Receptor AntagonistsGuanidinesReceptors, Purinergic P2X7Quinolinesdicyandiamido

Autor:innen und Institutionen

  • School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
  • Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia.

ORCID-Profile: Michael Kassiou

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Garrett, T. R., Gilchrist, J., McKenzie, A. D. J., Larik, F. A., Danon, J. J., Werry, E. L., & Kassiou, M. (2024). An Investigation on Linker Modifications of Cyanoguanidine‐Based P2X7 Receptor Antagonists. ChemMedChem. https://doi.org/10.1002/cmdc.202400163

Vancouver

Garrett TR, Gilchrist J, McKenzie ADJ, Larik FA, Danon JJ, Werry EL, et al. An Investigation on Linker Modifications of Cyanoguanidine‐Based P2X7 Receptor Antagonists. ChemMedChem. 2024. doi:10.1002/cmdc.202400163

BibTeX
@article{Garrett2024,
  author = {Garrett, Taylor R and Gilchrist, Jayson and McKenzie, Andre D J and Larik, Fayaz Ali and Danon, Jonathan J and Werry, Eryn L and Kassiou, Michael},
  title = {An Investigation on Linker Modifications of Cyanoguanidine‐Based P2X7 Receptor Antagonists},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400163}
}
Kostenlos starten →